Physician profile
Michael Schopis
NPI 1386175123
$9,888.80
in general payments reported to CMS, 2019-2025
22 companies · $4,828 in 2025
The $4,828 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,967 · 2024: $3,093 · 2025: $4,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,888.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,168.59 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,475.08 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,062.84 | 2023-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $532.03 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $459.74 | 2023-2025 | Sucraid |
| Pfizer INC. | $442.24 | 2024-2025 | |
| Genzyme Corporation | $423.21 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $390.30 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $388.02 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $279.10 | 2023-2025 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $199.44 | 2023-2025 | Entyvio |
| Lilly USA, LLC | $162.22 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $160.13 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $148.79 | 2023-2024 | Linzess |
| Celgene Corporation | $113.69 | 2023-2024 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $102.12 | 2023 | Conmed Generators, Conmed Biliary |
| Braintree Laboratories, INC. | $100.71 | 2023-2024 | Sutab, Suflave |
| Olympus America INC. | $100.32 | 2023 | Visiglide |
| Ipsen Biopharmaceuticals, INC | $78.70 | 2025 | Iqirvo |
| Exact Sciences Corporation | $52.93 | 2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $29.76 | 2025 | Rezdiffra |
| Galderma Laboratories, L.P. | $18.84 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schopis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.